EU Is Racing to Secure US Trade Deal and Preparing for the Worst
Officials in Brussels are prepared to stomach an unbalanced agreement that favors the US if that's what is required to break the impasse before the deadline. But the two sides have yet to yield a decisive breakthrough despite an earlier round of negotiations in Washington last week, according to people familiar with the matter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Pixalate's June 2025 Delisted Mobile Apps Reports: 46,331 Apps Delisted from Google Play Store & 45,685 from Apple App Store
Pixalate research finds 12,790 apps delisted from the United States (U.S.) Google Play Store were ad-enabled (e.g., had an file), while 3,789 apps delisted from the Apple App Store were ad-enabled London, July 21, 2025 (GLOBE NEWSWIRE) -- Pixalate, the leading ad fraud protection, privacy, and compliance analytics platform, today released the June 2025 Delisted Mobile Apps Reports for the United States (U.S.) Apple App Store and Google Play Store. The reports analyze apps delisted in June, including those enabled for programmatic advertising. The reports include a list of the top delisted apps by app store, enabled for programmatic advertising (based on the presence of an file). The report identifies applications that are no longer available for download from the U.S. Apple App Store and Google Play Store, according to Pixalate's data. Delisted apps do not indicate which party initiated the delisting action, i.e., Apple, Google, or the app developer. While some apps are delisted for benign reasons, others are removed due to more nefarious behaviors, including ad fraud and non-compliance with privacy regulations or app store policies, which may expose advertisers to potential financial or legal risks. Because apps can be delisted for various reasons, Pixalate neither asserts nor assigns a reason for any delisting action. Additionally, it is generally not publicly available information as to who the initiator of the delisting is, so it is often not possible to know whether the app store or the developer triggered the research focuses on app profile information. It provides various insights observed in the programmatic advertising bid stream, such as the developer's country of registry, the level of app abandonment, and the number of delisted apps with advertising (as indicated by an file). Key Findings: Delisted Mobile Apps (June 2025) Google Play Store Delisted apps: 46,331 apps delisted in June 2025, representing a 7% decrease from May 2025 12,790 apps delisted were enabled for programmatic advertising (i.e., had declared an file) in June 2025 Google Play Store: Top 5 Delisted Apps in June 2025 (by downloads) Rank App ID App Title Estimated Downloads Developer Name 1 upday news for Samsung 100.0M upday GmbH & Co. KG 2 Doubtnut for NCERT, JEE, NEET 50.0M Doubtnut: Doubt Solving & Video Solutions App 3 RYT - Music Player 50.0M Alaskavinh 4 Shoot Hunter-Gun Killer 50.0M RAY3D 5 Masha and the Bear Child Games 50.0M DTC Lab Apple App Store Delisted apps: 45,685 apps delisted in June 2025, up 17% from June 2025 3,789 apps delisted were enabled for programmatic advertising in June 2025 Apple App Store: Top 5 Delisted Apps in June 2025 (by downloads) Rank App ID App Title Estimated User Ratings Developer Name 1 1316355277 Where is my Train : Live Train 301.8K NISHI SAHLOT 2 1525688578 月亮播放器 - 高清电影电视剧影视视频播放器 165.1K 智熙 郑 3 1266129086 叶罗丽精灵梦——魔法公主换装游戏 98.9K 丹 李 4 1467924305 Mother Life Simulator Game 72.7K Nadeem Munawar 5 293778748 PAC-MAN 69.3K BANDAI NAMCO Entertainment America Inc. To compile this research, Pixalate's data science and analyst team analyzed over 2 million apps delisted from the United States Apple App Store and over 5.8 million apps delisted from the United States Google Play Store between January 2021 and June 2025. Download the complete reports here: Google Play Store Apple App Store About Pixalate Pixalate is a global platform specializing in privacy compliance, ad fraud prevention, and digital ad supply chain data intelligence. Founded in 2012, Pixalate is trusted by regulators, data researchers, advertisers, publishers, ad tech platforms, and financial analysts across the Connected TV (CTV), mobile app, and website ecosystems. Pixalate is accredited by the MRC for the detection and filtration of Sophisticated Invalid Traffic (SIVT). Disclaimer The content of this press release, and the June 2025 US Google Play Store & US Apple App Store Delisted Mobile Apps Reports (the 'Reports'), reflect Pixalate's opinions with respect to factors that Pixalate believes may be useful to the digital media industry. Any data shared is grounded in Pixalate's proprietary technology and analytics, which Pixalate is continuously evaluating and updating. Any references to outside sources should not be construed as endorsements. Pixalate's opinions are just that, opinions, which means that they are neither facts nor guarantees. Pixalate is sharing this data not to impugn the standing or reputation of any entity, person or app, but, instead, to report findings and trends pertaining to programmatic advertising activity across mobile apps in the time period studied. CONTACT: Nina Talcott ntalcott@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
AstraZeneca announces $50 billion U.S. manufacturing investment, matching its big pharma peers
AstraZeneca (AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers that have, combined, announced more than $200 billion in investments in coming years. The commitment is the largest investment to-date, according to the company in a statement Monday. It includes expansions of current sites, including in Maryland and Massachusetts, as well as new facility in Virginia. "The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of the-art centre will produce small molecules, peptides and oligonucleotides," the company said. U.K.-based AstraZeneca said it currently relies on the U.S. market for 42% of its revenues, and hopes to increase the U.S. market share to 50% with this move. Its known for oncology drugs Tagrisso and Imfinzi. AstraZeneca's leadership was scheduled to speak at an event in Washington, D.C. Monday evening, flanked by Virginia Gov. Glenn Youngkin and U.S. Commerce Dept. representatives. "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030," said CEO Pascal Soriot. The strategy to invest billions in manufacturing is one being deployed by the industry in order to curry favor with President Donald Trump and his re-shoring agenda, and in hopes of avoiding strict tariffs on imported drug components manufactured abroad. Some of the largest investment commitments to-date have been Johnson & Johnson's (JNJ) $55 billion announcement and Eli Lilly's (LLY) $50 billion. With a previous $3.5 billion announced in November 2024, the new $50 billion commitment puts AstraZeneca in second. Trump has promised the pharma industry will face tariffs starting August 1. Industry leaders have pleaded with the administration for more time, and Trump has hinted the tariffs could be phased-in, as the companies work to bring their manufacturing onshore. The industry has been hoping Trump would ease up on the tariffs, in exchange for the onshoring commitments. J&J CFO Joe Wolk recently told Yahoo Finance the company has met with Trump and tried to persuade him to understand that the industry can't move facilities overnight. Meanwhile, others, like Eli Lilly CEO Dave Ricks, are hoping the administration would halt tariffs on the industry altogether. Ricks previously said that if the administration wants a commitment to make generics and other low-revenue products in exchange for no tariffs, its something the industry could consider. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Steel Dynamics posts downbeat quarterly results on raw material costs
(Reuters) -Steel Dynamics on Monday posted second-quarter results below Wall Street estimates, as raw material costs increased and uncertainty around U.S. trade policy impacted demand. Shares of the Fort Wayne, Indiana-based company fell more than 4% after hours. U.S. steelmakers stand to benefit from President Donald Trump's tariffs on steel imports pushing up prices, but the levies also threaten to raise raw material costs. "The uncertainty regarding trade policy continues to cause hesitancy in customer order patterns across our businesses, despite healthy underlying demand factors," CEO Mark Millett said in the statement. "We strongly believe that as individual country trade agreements are negotiated and trade policy is generally stabilized in the coming months, strong pent up demand for our products will result." Steel Dynamics also reiterated an inventory overhang in its coated flat rolled products due to imports. The company's second-quarter adjusted profit of $2.01 per share came in below analysts' estimate of $2.10, according to data compiled by LSEG. Revenue for the quarter ended June 30 was $4.56 billion, missing Wall Street expectations of $4.76 billion. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
